Skip to content
2000
Volume 14, Issue 8
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

The increasing frequency of multidrug-resistant bacteria and a recent slowing in the development of new antimicrobial agents place mankind in a state of emergency with regard to the threat of new bacterial infections. Antibacterial peptides (AMPs) are considered an important class of molecules to develop against bacteria. AMPs have been known for many years but very few have yet been extensively used in clinical practice, mainly because of their general toxicity and manufacturing cost. Now, thanks to new technologies for screening and development, interest in these molecules has grown. Many new AMPs have been discovered and some are under evaluation for the development of new antibacterial therapeutics. Here we review the major AMPs currently used in clinical practice and others in the phase of preclinical and clinical development.

Loading

Article metrics loading...

/content/journals/cpps/10.2174/138920371408131227155308
2013-12-01
2025-09-03
Loading full text...

Full text loading...

/content/journals/cpps/10.2174/138920371408131227155308
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test